Researchers used a Markov cohort model to assess the cost-effectiveness of semaglutide vs ESG over 5 years in people with class II obesity. ESG led to better weight loss outcomes and added more QALYs relative to semaglutide.
Researchers used a Markov cohort model to assess the cost-effectiveness of semaglutide vs ESG over 5 years in people with class II obesity , with the model costs based on the US healthcare system.The model simulated hypothetical patients with class II obesity who received ESG , semaglutide, or no treatment .
The model derived clinical data for the first year from two randomized clinical trials, STEP 1 and MERIT ; for the following years, data were derived from published studies and publicly available data sources.ESG led to better weight loss outcomes and added 0.06 more QALYs relative to semaglutide in the modelled patients over the 5-year time horizon; about 20% of the patients receiving semaglutide dropped out owing to medication intolerance or other reasons.
The annual price of semaglutide would need to be reduced from $13,618 to $3591 to achieve nondominance compared with ESG."The strategic choice of cost saving yet effective treatment such as ESG compared with semaglutide for specific patient groups could help alleviate the potential budget strain expected from the use of semaglutide," the authors wrote.
Cost-Effectiveness Semaglutide ESG Obesity Weight Loss Qalys
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Endoscopic Sleeve Gastroplasty More Cost-Effective Long Term Than Semaglutide for Treating ObesitySemaglutide is an effective treatment option for weight loss, but its cost-effectiveness over the long term compared with ESG needs to be considered.
Read more »
Vanishing Fat: Semaglutide’s Triumph Over HIV Liver DiseaseScience, Space and Technology News 2024
Read more »
Semaglutide Benefits in HFpEF Take a Step Beyond Weight LossDrs Piña and Kosiborod discuss semaglutide in obesity-related HF with and without diabetes. Both STEP HFpEF trials show similar HF benefits despite less weight loss in patients with diabetes.
Read more »
Effect of Prior Anti-Obesity Drug Use on Weight Loss Outcomes of Semaglutide InjectionsA retrospective study evaluated the impact of prior anti-obesity drug use on the weight loss outcomes of weekly semaglutide injections in patients with overweight or obesity. The study found heterogeneous results and aimed to determine the difference in weight loss percentage between patients with and without prior anti-obesity treatment.
Read more »
Prior Anti-Obesity Drug Use Curbs Weight Loss on SemaglutidePatients who were overweight or obese lost more weight taking semaglutide if they hadn't previously taken another anti-obesity medication.
Read more »
Semaglutide Beneficial in HFpEF Patients With DiabetesIn patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
Read more »